May 09, 2026 01:25 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Cloud over Tamil Nadu government formation as Governor asks Vijay to prove majority | 1 Year of Operation Sindoor: PM Modi says it showed India’s firm response to terror | ‘Larger conspiracy ahead of PM Modi’s visit’: BJP on killing of Suvendu Adhikari’s aide | ‘My car was on OLX for sale’: Siliguri owner says number plate used in Suvendu aide assassination may have been cloned online | ‘Pre-planned political assassination’: BJP’s Swapan Dasgupta on Suvendu aide’s killing | BJP leader Suvendu Adhikari's personal secretary shot dead in West Bengal's Madhyamgram | Mamata Banerjee to move Supreme Court against Bengal post-poll violence, refuses to quit | Who after Mamata in Bengal? Amit Shah to meet BJP MLA-elects ahead of May 9 oath | Vijay’s TVK seeks Congress, Left support after falling short of majority in Tamil Nadu | Jolt to TMC! Supreme Court rejects plea challenging central staff deployment at Bengal counting centres
Instas Pharma

Abu Dhabi Investment Authority to buy stake in Instas Pharma

| @indiablooms | Apr 27, 2022, at 05:48 pm

The Abu Dhabi Investment Authority (ADIA), a sovereign wealth fund owned by the Emirate of Abu Dhabi, is going to acquire about 3 percent in Intas Pharmaceuticals for $250-$270 million (Rs 2,000 crore) at a valuation of $8.5 billion (Rs 65,000 crore), media reports said.

It will acquire the 3 percent stake from current investor Temasek Holdings, which presently holds about 10 percent in the Indian drug company, ET reported.

The Chudgar family, currently, owns 84 percent of the company, while homegrown PE fund ChrysCapital owns 6 percent, said the report.

ADIA has wide exposure in India with assets under management worth $800 billion., it added.

Its has invested in major Indian companies like Flipkart, Reliance Retail, Mindspace REIT, HDFC Capital, Mphasis, Paytm, Nykaa and Mobikwik.

Since 2018, ADIA has invested more than $3 billion in India, the report noted.

Intas Pharma is the seventh-largest domestic formulations company, with nearly 30 percent of its turnover locally, about 40 percent from the UK and European markets, and remaining from the United States and other markets.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm